Another promising candidate is the serum-soluble fragment of cytokeratin 19 (CK 19), CYFRA 21-1, that is associated with tumor progression and poor postoperative outcomes in patients with intrahepatic cholangiocarcinoma [53]. This evidence concerns the gene KRT19 and intrahepatic cholangiocarcinoma.